Related Experiment Videos
Methods for clinical research involving cannabis administration
David A Gorelick1, Stephen J Heishman
1Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA.
Methods in Molecular Medicine
|March 2, 2006
Summary
Clinical studies on cannabis effects and dependence treatments require controlled administration. Safe research involves careful subject screening, monitoring for adverse events like anxiety and psychosis, and ensuring participants return to baseline.
Area of Science:
- Pharmacology
- Clinical Research
- Cannabis Science
Background:
- Understanding cannabis effects and developing treatments for cannabis dependence necessitate clinical studies involving controlled administration.
- Cannabis administration methods include smoking, oral, and intravenous routes, each with unique pharmacokinetic profiles and safety considerations.
- Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive component, with synthetic oral forms (dronabinol) available as medication.
Purpose of the Study:
- To outline the requirements for safe and effective clinical studies involving cannabis administration.
- To detail various administration routes for cannabis and their associated dose variability and safety margins.
- To identify potential acute adverse effects and necessary screening and monitoring protocols for research participants.
Main Methods:
- Review of cannabis administration routes: smoked, oral (synthetic THC/dronabinol), and intravenous THC.
- Identification of acute adverse effects associated with cannabis administration.
- Establishment of screening criteria for research subjects to mitigate risks.
- Definition of monitoring parameters (heart rate, blood pressure, mental status) during administration.
- Protocols for subject discharge post-study.
Main Results:
- Smoked cannabis exhibits high dose variability; oral synthetic THC has variable pharmacokinetics but a better safety margin; intravenous THC allows precise control.
- Acute adverse effects include cardiovascular changes, pulmonary irritation, cognitive/motor impairment, and psychiatric symptoms (anxiety, paranoia, psychosis).
- Rigorous subject screening and continuous monitoring are crucial for managing risks associated with cannabis administration in clinical settings.
Conclusions:
- Controlled cannabis administration in clinical research requires careful consideration of administration route, subject selection, and monitoring.
- Adherence to safety protocols, including pre-study screening and intra-study monitoring, is essential to minimize adverse events.
- Ensuring participants return to their baseline status post-administration is a critical component of ethical research conduct.